https://www.selleckchem.com/pr....oducts/ecc5004-azd50
The optimal timing of initiating antiviral treatment for immune-tolerant (IT) patients remains unknown. We conducted this study in liver biopsy-proven IT patients to compare the long-term outcomes of untreated and treated patients suffering non-cirrhotic chronic hepatitis B (CH. This retrospective cohort study recruited 171 consecutive treatment-naïve CHB patients who completed liver biopsy test. Patients were stratified into IT (n = 6, mildly-active (MA; n = 31), immune-active (IA; n = 8, according to alanine aminotransfe
Like
Comment
Share
